Virios Therapeutics (NASDAQ:VIRI) Stock Price Up 1.7% – Still a Buy?

Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) traded up 1.7% during mid-day trading on Thursday . The company traded as high as $3.1799 and last traded at $3.08. 20,139 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,049,645 shares. The stock had previously closed at $3.03.

Virios Therapeutics Stock Up 1.7%

The firm’s 50 day simple moving average is $4.43 and its 200 day simple moving average is $5.09. The company has a market cap of $59.31 million, a price-to-earnings ratio of -11.41 and a beta of 1.58.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.